Literature DB >> 33506768

IO + IO = More to Know:: The Uncertain Potential for Combined Interventional and Immuno-Oncology.

Daniel B Brown1, Rajiv Agarwal2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33506768      PMCID： PMC8180312          DOI： 10.1016/j.jvir.2020.09.027

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN： 1051-0443            Impact factor:   3.464


× No keyword cloud information.
  11 in total

1.  Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.

Authors:  Chenyang Zhan; David Ruohoniemi; Krishna P Shanbhogue; Jason Wei; Theodore H Welling; Ping Gu; James S Park; Nabil N Dagher; Bedros Taslakian; Ryan M Hickey
Journal:  J Vasc Interv Radiol       Date:  2019-08-14       Impact factor: 3.464

2.  Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis.

Authors:  Konstantin S Leppelmann; Meghan J Mooradian; Suvranu Ganguli; Raul N Uppot; Kei Yamada; Zubin Irani; Eric P Wehrenberg-Klee; Leyre Zubiri; Kerry L Reynolds; Ronald S Arellano; Joshua A Hirsch; Ryan J Sullivan; Florian J Fintelmann
Journal:  J Vasc Interv Radiol       Date:  2021-01-19       Impact factor: 3.464

Review 3.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 4.  Immunity, tolerance and autoimmunity in the liver: A comprehensive review.

Authors:  Derek G Doherty
Journal:  J Autoimmun       Date:  2015-09-07       Impact factor: 7.094

5.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Authors:  Austin G Duffy; Susanna V Ulahannan; Oxana Makorova-Rusher; Osama Rahma; Heiner Wedemeyer; Drew Pratt; Jeremy L Davis; Marybeth S Hughes; Theo Heller; Mei ElGindi; Ashish Uppala; Firouzeh Korangy; David E Kleiner; William D Figg; David Venzon; Seth M Steinberg; Aradhana M Venkatesan; Venkatesh Krishnasamy; Nadine Abi-Jaoudeh; Elliot Levy; Brad J Wood; Tim F Greten
Journal:  J Hepatol       Date:  2016-11-02       Impact factor: 25.083

6.  Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.

Authors:  Alexa O Levey; Mohammad Elsayed; David H Lawson; Robert M Ermentrout; Ragini R Kudchadkar; Zachary L Bercu; Melinda L Yushak; Janice Newsome; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2019-11-04       Impact factor: 2.740

Review 7.  Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.

Authors:  B El Osta; F Hu; R Sadek; R Chintalapally; S-C Tang
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-08       Impact factor: 6.312

8.  Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.

Authors:  Qu Zhang; Jia Luo; Han Si; Shaad E Abdullah; Brandon W Higgs; Todd Hembrough; Song Wu; Chen Gao; Wenjing Xu; Phillip A Dennis; Michiel S van der Heijden; Neil H Segal; Jamie E Chaft; J Carl Barrett; Matthew D Hellmann
Journal:  Cancer Discov       Date:  2020-08-14       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.